Century Therapeutics price to book ratio IPSC
Market value divided by the book value of the company's net assets, since 2021.
- Today, Nov 2, 2026
- 1.2×
- 5-year median
- 1.0×
- Against its 5-year history
- 55th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.2× to 3.9×
- Peer median
- 4.9×
Century Therapeutics' price to book ratio is 1.2× as of Nov 2, 2026.
That is above its 5-year median of 1.0×, close to the middle of its last 5 years.
Over that time it ranged from 0.2× in Aug 2025 to 3.9× in Aug 2021.
The median for 4 biotech stocks of a similar size is 4.9×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.2× | 0.5× | 2.9× |
| 2025 | 0.5× | 0.2× | 0.5× |
| 2024 | 0.5× | 0.5× | 1.8× |
| 2023 | 0.9× | 0.3× | 0.9× |
| 2022 | 0.9× | 0.9× | 2.0× |
| 2021 | 2.0× | 1.9× | 3.9× |
Against its peers
Companies in Biotechnology nearest Century Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| IPSCCentury Therapeutics | 1.2× |
| PLXProtalix BioTherapeutics | 2.9× |
| MGTXMeiraGTx | 4.2× |
| VCELVericel | 5.6× |
| ADMAAdma Biologics | 6.1× |
| Peer median | 4.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Century Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.